Is CNTB or INMB more profitable?

INmune Bio's return on equity of -103.03% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Connect Biopharma N/A -122.29% -97.07% INmune Bio N/A -103.03% -77.66%

Is CRBP or INMB more profitable?

Corbus Pharmaceuticals' return on equity of -70.89% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets Corbus Pharmaceuticals N/A -70.89% -61.78% INmune Bio N/A -103.03% -77.66%

Is INMB or HURA more profitable?

INmune Bio's return on equity of -103.03% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -103.03% -77.66% TuHURA Biosciences N/A -156.12% -105.38%

Is INMB or SPRB more profitable?

INmune Bio's return on equity of -103.03% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -103.03% -77.66% Spruce Biosciences N/A -155.40% -101.67%

Is CRDL or INMB more profitable?

INmune Bio's return on equity of -103.03% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -229.43% -165.60% INmune Bio N/A -103.03% -77.66%

INmune Bio (INMB) Competitors

$1.21 -0.01 (-0.82%)

Closing price 04:00 PM Eastern

Extended Trading

$1.23 +0.02 (+1.24%)

As of 06:33 PM Eastern

Compare

INMB vs. CNTB, CRBP, HURA, SPRB, and CRDL

Should you buy INmune Bio stock or one of its competitors? MarketBeat compares INmune Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with INmune Bio include Connect Biopharma (CNTB), Corbus Pharmaceuticals (CRBP), TuHURA Biosciences (HURA), Spruce Biosciences (SPRB), and Cardiol Therapeutics (CRDL). These companies are all part of the "pharmaceutical products" industry.

How does INmune Bio compare to Connect Biopharma?

Connect Biopharma (NASDAQ:CNTB) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

INmune Bio has lower revenue, but higher earnings than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	2,182.61	-$55.48M	-$1.15	N/A
INmune Bio	$50K	643.24	-$45.93M	-$1.67	N/A

INmune Bio's return on equity of -103.03% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-122.29%	-97.07%
INmune Bio	N/A	-103.03%	-77.66%

In the previous week, Connect Biopharma and Connect Biopharma both had 1 articles in the media. Connect Biopharma's average media sentiment score of 1.91 beat INmune Bio's score of 0.93 indicating that Connect Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Connect Biopharma	Very Positive
INmune Bio	Positive

Connect Biopharma presently has a consensus price target of $7.20, indicating a potential upside of 246.15%. INmune Bio has a consensus price target of $8.00, indicating a potential upside of 561.16%. Given INmune Bio's higher probable upside, analysts clearly believe INmune Bio is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
INmune Bio	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17

58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 12.7% of INmune Bio shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by company insiders. Comparatively, 21.4% of INmune Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Connect Biopharma has a beta of -0.22, meaning that its stock price is 122% less volatile than the broader market. Comparatively, INmune Bio has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

Summary

Connect Biopharma beats INmune Bio on 8 of the 14 factors compared between the two stocks.

How does INmune Bio compare to Corbus Pharmaceuticals?

Corbus Pharmaceuticals (NASDAQ:CRBP) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.7% of INmune Bio shares are owned by institutional investors. 3.5% of Corbus Pharmaceuticals shares are owned by insiders. Comparatively, 21.4% of INmune Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Corbus Pharmaceuticals currently has a consensus target price of $42.00, indicating a potential upside of 445.45%. INmune Bio has a consensus target price of $8.00, indicating a potential upside of 561.16%. Given INmune Bio's higher possible upside, analysts plainly believe INmune Bio is more favorable than Corbus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
INmune Bio	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17

INmune Bio has higher revenue and earnings than Corbus Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A
INmune Bio	$50K	643.24	-$45.93M	-$1.67	N/A

Corbus Pharmaceuticals has a beta of 2.57, meaning that its share price is 157% more volatile than the broader market. Comparatively, INmune Bio has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

Corbus Pharmaceuticals' return on equity of -70.89% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%
INmune Bio	N/A	-103.03%	-77.66%

In the previous week, Corbus Pharmaceuticals had 4 more articles in the media than INmune Bio. MarketBeat recorded 5 mentions for Corbus Pharmaceuticals and 1 mentions for INmune Bio. Corbus Pharmaceuticals' average media sentiment score of 1.05 beat INmune Bio's score of 0.93 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Corbus Pharmaceuticals	Positive
INmune Bio	Positive

Summary

Corbus Pharmaceuticals beats INmune Bio on 8 of the 14 factors compared between the two stocks.

How does INmune Bio compare to TuHURA Biosciences?

INmune Bio (NASDAQ:INMB) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

INmune Bio currently has a consensus price target of $8.00, suggesting a potential upside of 561.16%. TuHURA Biosciences has a consensus price target of $9.00, suggesting a potential upside of 332.69%. Given INmune Bio's higher probable upside, analysts clearly believe INmune Bio is more favorable than TuHURA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

TuHURA Biosciences has lower revenue, but higher earnings than INmune Bio. TuHURA Biosciences is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	643.24	-$45.93M	-$1.67	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A

INmune Bio has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market.

12.7% of INmune Bio shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 21.4% of INmune Bio shares are held by insiders. Comparatively, 0.2% of TuHURA Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

INmune Bio's return on equity of -103.03% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-103.03%	-77.66%
TuHURA Biosciences	N/A	-156.12%	-105.38%

In the previous week, TuHURA Biosciences had 1 more articles in the media than INmune Bio. MarketBeat recorded 2 mentions for TuHURA Biosciences and 1 mentions for INmune Bio. INmune Bio's average media sentiment score of 0.93 equaled TuHURA Biosciences'average media sentiment score.

Company	Overall Sentiment
INmune Bio	Positive
TuHURA Biosciences	Positive

Summary

INmune Bio beats TuHURA Biosciences on 9 of the 14 factors compared between the two stocks.

How does INmune Bio compare to Spruce Biosciences?

INmune Bio (NASDAQ:INMB) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

In the previous week, Spruce Biosciences had 2 more articles in the media than INmune Bio. MarketBeat recorded 3 mentions for Spruce Biosciences and 1 mentions for INmune Bio. Spruce Biosciences' average media sentiment score of 1.12 beat INmune Bio's score of 0.93 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
INmune Bio	Positive
Spruce Biosciences	Positive

INmune Bio's return on equity of -103.03% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-103.03%	-77.66%
Spruce Biosciences	N/A	-155.40%	-101.67%

12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

INmune Bio currently has a consensus target price of $8.00, indicating a potential upside of 561.16%. Spruce Biosciences has a consensus target price of $169.67, indicating a potential upside of 260.00%. Given INmune Bio's higher probable upside, equities analysts clearly believe INmune Bio is more favorable than Spruce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Spruce Biosciences has higher revenue and earnings than INmune Bio. Spruce Biosciences is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	643.24	-$45.93M	-$1.67	N/A
Spruce Biosciences	$4.91M	26.40	-$38.97M	-$36.60	N/A

INmune Bio has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.11, meaning that its stock price is 211% more volatile than the broader market.

Summary

INmune Bio and Spruce Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does INmune Bio compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Cardiol Therapeutics has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market. Comparatively, INmune Bio has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of INmune Bio shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 21.4% of INmune Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cardiol Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 709.52%. INmune Bio has a consensus target price of $8.00, suggesting a potential upside of 561.16%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Cardiol Therapeutics is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
INmune Bio	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17

In the previous week, Cardiol Therapeutics and Cardiol Therapeutics both had 1 articles in the media. Cardiol Therapeutics' average media sentiment score of 1.89 beat INmune Bio's score of 0.93 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cardiol Therapeutics	Very Positive
INmune Bio	Positive

INmune Bio's return on equity of -103.03% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
INmune Bio	N/A	-103.03%	-77.66%

Cardiol Therapeutics has higher earnings, but lower revenue than INmune Bio. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
INmune Bio	$50K	643.24	-$45.93M	-$1.67	N/A

Summary

INmune Bio beats Cardiol Therapeutics on 8 of the 14 factors compared between the two stocks.

Get INmune Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INMB vs. The Competition

Export

Metric	INmune Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$32.16M	$3.28B	$6.43B	$11.71B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-0.72	18.99	24.49	23.62
Price / Sales	643.24	290.48	500.49	105.27
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	1.38	8.00	10.43	6.70
Net Income	-$45.93M	$23.89M	$3.56B	$337.26M
7 Day Performance	-8.33%	-3.49%	-1.38%	-1.41%
1 Month Performance	-15.38%	1.02%	0.86%	1.15%
1 Year Performance	-84.64%	34.39%	19.43%	22.61%

INmune Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INMB INmune Bio	1.5991 of 5 stars	$1.21 -0.8%	$8.00 +561.2%	-84.1%	$32.16M	$50K	N/A	10
CNTB Connect Biopharma	3.9766 of 5 stars	$2.34 -6.0%	$7.20 +207.7%	+171.4%	$147.34M	$233K	N/A	110
CRBP Corbus Pharmaceuticals	4.364 of 5 stars	$7.75 -2.0%	$42.00 +441.9%	-16.4%	$146.56M	N/A	N/A	40
HURA TuHURA Biosciences	2.0804 of 5 stars	$2.24 -0.9%	$9.00 +301.8%	-29.9%	$143.92M	N/A	N/A	N/A
SPRB Spruce Biosciences	2.8076 of 5 stars	$50.70 -1.1%	$176.60 +248.3%	+989.6%	$141.11M	N/A	N/A	20	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INMB) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

INmune Bio (INMB) Competitors

INMB vs. CNTB, CRBP, HURA, SPRB, and CRDL

How does INmune Bio compare to Connect Biopharma?

Summary

How does INmune Bio compare to Corbus Pharmaceuticals?

Summary

How does INmune Bio compare to TuHURA Biosciences?

Summary

How does INmune Bio compare to Spruce Biosciences?

Summary

How does INmune Bio compare to Cardiol Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB vs. The Competition

INmune Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

INmune Bio (INMB) Competitors

INMB vs. CNTB, CRBP, HURA, SPRB, and CRDL

How does INmune Bio compare to Connect Biopharma?

Which has better earnings & valuation, CNTB or INMB?

Is CNTB or INMB more profitable?

Does the media refer more to CNTB or INMB?

Do analysts rate CNTB or INMB?

Do institutionals & insiders have more ownership in CNTB or INMB?

Which has more risk and volatility, CNTB or INMB?

Summary

How does INmune Bio compare to Corbus Pharmaceuticals?

Do insiders & institutionals have more ownership in CRBP or INMB?

Do analysts recommend CRBP or INMB?

Which has preferable valuation & earnings, CRBP or INMB?

Which has more risk & volatility, CRBP or INMB?

Is CRBP or INMB more profitable?

Does the media refer more to CRBP or INMB?

Summary

How does INmune Bio compare to TuHURA Biosciences?

Do analysts prefer INMB or HURA?

Which has better valuation & earnings, INMB or HURA?

Which has more volatility and risk, INMB or HURA?

Do insiders and institutionals have more ownership in INMB or HURA?

Is INMB or HURA more profitable?

Does the media prefer INMB or HURA?

Summary

How does INmune Bio compare to Spruce Biosciences?

Does the media prefer INMB or SPRB?

Is INMB or SPRB more profitable?

Do insiders & institutionals believe in INMB or SPRB?

Do analysts rate INMB or SPRB?

Which has higher valuation & earnings, INMB or SPRB?

Which has more volatility & risk, INMB or SPRB?

Summary

How does INmune Bio compare to Cardiol Therapeutics?

Which has more volatility & risk, CRDL or INMB?

Do insiders and institutionals hold more shares of CRDL or INMB?

Do analysts recommend CRDL or INMB?

Does the media favor CRDL or INMB?

Is CRDL or INMB more profitable?

Which has better valuation and earnings, CRDL or INMB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB vs. The Competition

INmune Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools